Group 1: Investor Relations Activities - The investor relations activities included specific object research, analyst meetings, media interviews, performance briefings, press releases, roadshows, and online meetings [2] - Participants included representatives from Zheshang Securities, Minsheng Securities, Tianhong Fund, Huatai Securities, Ping An Securities, and Ping An Pension [2] - The activities took place from November 19 to November 21, 2024, in the company meeting room [2] Group 2: Company Performance Insights - The third-quarter report for 2024 was discussed, focusing on operational management, product development, market expansion, and team integration [2] - The company anticipates growth in the macromolecule application direction, particularly in antibody new drug projects, with a focus on expanding recombinant proteins, nucleic acids, and blood products [2] - There is an increasing trend of domestic substitutes for imported products, with opportunities for repeat orders as new drug projects transition to commercial production [2] Group 3: Instrumentation Strategy - The acquisition of Saipu Instruments and Fuli Instruments aims to create a comprehensive chromatography technology platform, providing competitive overall solutions [2] - The company is integrating its "materials + instruments" marketing team to enhance service and understand customer project needs, thereby expanding the "aftermarket" application opportunities for consumables [2]

Group 1: Investor Relations Activities - The investor relations activities included specific object research, online meetings, and discussions on Q3 performance [1] - Participants included representatives from Dongwu Securities, Huashang Fund, CITIC Securities, and others [1] - The meetings took place from November 11 to November 12, 2024, in the company conference room [1] Group 2: Company Performance Insights - The demand for GLP-1 has increased significantly, providing more opportunities for domestic filler suppliers [1] - The company has a competitive product line in the GLP-1 drug development sector, contributing to the growth of small molecule business in Q3 [1] - Challenges in the spectrometer business include reduced demand for instrument purchases and declining sales prices due to industry competition [1] Group 3: Strategic Responses - The company has integrated the "filler + consumables" marketing team since Q4 last year, showing positive results in instrument sales [1] - Future strategies include optimizing R&D resources to focus on key product upgrades and controlling long-term project investments [1] - The goal is to achieve profitability in the upcoming year [1]

Group 1: Company Performance and Strategy - The company discussed its Q3 2024 performance during investor meetings, aligning with the content of its announcements and regular reports [1] - The company has established a dedicated application technology team for the GLP-1 project, leveraging years of project experience to optimize purification solutions for clients [1] Group 2: Product Development and Market Position - The company has a competitive edge in the GLP-1 project due to diverse purification processes and a rich variety of products, particularly in hard capsule products [1] - The slow iteration of soft capsule products is attributed to the need for complete autonomy in the development of the third-generation product, which is currently in the market promotion phase with small-scale client applications [2]

Group 1: Financial Performance - The company's revenue for the first three quarters of 2024 reached 550 million yuan, a year-on-year increase of 21.85% [1] - Excluding the newly consolidated revenue from Fuli Instruments of 103 million yuan, the organic revenue was 447 million yuan, remaining stable compared to the previous year [1] - The overall gross margin for the first three quarters was 71.06%, a decrease of nearly 8 percentage points year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 42 million yuan, with a year-on-year growth of 27.32% [2] Group 2: Cost Management - Total expenses for sales, management, and R&D for the first three quarters amounted to 317 million yuan, a decrease of approximately 1.2% year-on-year [1] - The company implemented strict cost control measures starting from the second half of 2023, effectively managing expense growth [2] - The expense ratios were approximately 18% for operating expenses, 13% for management expenses, and 21% for R&D expenses [3] Group 3: Market and Product Development - The chromatography consumables business maintained a growth rate of over 30%, while the optical and IVD businesses remained stable [1] - The company is focusing on the overseas market, with 80% of overseas revenue coming from end customers, primarily pharmaceutical companies [2] - The company plans to enhance its product competitiveness and optimize marketing strategies to capture opportunities in the biopharmaceutical market [2] Group 4: Strategic Acquisitions and Future Outlook - The company has acquired two instrument companies, aiming to build a chromatography technology platform to compete with international leaders [1] - The company is optimistic about the long-term development prospects of the biopharmaceutical industry despite current market challenges [4] - Future growth is expected from the integration of Fuli Instruments and the optimization of the sales and R&D teams [3]

证券代码：688690 证券简称：纳微科技 公告编号：2024-077 苏州纳微科技股份有限公司 二、 回购股份的进展情况 根据《上海证券交易所上市公司自律监管指引第7号——回购股份》等相关规 定，公司在回购股份期间，应当在每个月的前3个交易日内公告截至上月末的回购 进展情况，现将公司回购股份进展情况公告如下： 截止2024年10月31日，公司通过上海证券交易所系统以集中竞价交易方式累 计回购公司股份3,048,822股，占公司总股本403,814,765股的比例为0.76%，回购 成交的最高价为22.18元/股、最低价为15.52元/股，支付的资金总额为人民币 60,642,811.16元（不含印花税、交易佣金等交易费用）。 本次回购股份符合法律法规的规定及公司回购股份方案。 三、 其他事项 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/1/31，由公司实际控制人、董事长江必旺博 士提议 | | --- | --- | | ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 苏州纳微科技股份有限公司（以下简称"公司"）第三届监事会第三次会议 于 2024 年 10 月 28 日以线上方式召开。会议应出席监事 3 名，实际出席 3 名， 符合《中华人民共和国公司法》和《苏州纳微科技股份有限公司章程》的有关规 定，会议决议合法、有效。 二、监事会会议审议情况 证券代码：688690 证券简称：纳微科技 公告编号：2024-075 苏州纳微科技股份有限公司 第三届监事会第三次会议决议公告 表决结果：通过。 具体内容详见公司同日刊登在上海证券交易所网站（www.sse.com.cn）的《苏 州纳微科技股份有限公司 2024 年第三季度报告》。 （二）审议通过《关于调整 2022 年、2024 年限制性股票激励计划授予价 格的议案》 鉴于公司 2023 年年度权益分派已于 2024 年 6 月 18 日实施完毕，监事会同 意公司根据《2022 年限制性股票激励计划（草案）》及《2024 年限制性股票激 （一）审议通过《关于公司<20 ...

Financial Performance - The company's operating revenue for Q3 2024 was RMB 20,998.02 million, an increase of 34.61% year-on-year[2] - The net profit attributable to shareholders for Q3 2024 was a loss of RMB 304.78 million, a decline of 142.59% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 965.17 million, a decrease of 644.37% year-on-year[2] - The basic earnings per share for Q3 2024 was -0.0076 RMB, down 142.94% from the previous year[2] - In the first three quarters of 2024, the company achieved operating revenue of RMB 550 million, a year-on-year increase of 21.85%[13] - Net profit attributable to shareholders for the first three quarters was RMB 42.0043 million, a year-on-year increase of 7.75%[13] - The net profit for Q3 2024 was CNY 41,282,330.84, an increase from CNY 28,046,231.10 in Q3 2023, representing a growth of approximately 47.4%[19] - The total comprehensive income for Q3 2024 was CNY 40,776,821.93, compared to CNY 28,748,939.23 in Q3 2023, indicating a year-over-year increase of about 42%[20] Research and Development - The company reported a total R&D investment of RMB 5,161.56 million in Q3 2024, accounting for 24.58% of operating revenue, a decrease of 4.62 percentage points year-on-year[3] - Research and development expenses for Q3 2024 amounted to ¥128,692,421.83, slightly down from ¥128,906,037.89 in Q3 2023[18] Assets and Liabilities - The total assets at the end of the reporting period were RMB 225,773.34 million, an increase of 6.17% compared to the end of the previous year[3] - Non-current assets totaled ¥1,087,968,237.70 as of Q3 2024, an increase from ¥948,091,690.29 in Q3 2023[16] - Total assets reached ¥2,257,733,372.74 in Q3 2024, compared to ¥2,126,568,288.37 in Q3 2023, marking an increase of 6.2%[16] - Total liabilities amounted to ¥405,592,619.31 in Q3 2024, a slight increase from ¥396,404,010.92 in Q3 2023[16] Cash Flow and Investments - Cash and cash equivalents decreased to RMB 254.14 million from RMB 339.76 million at the end of 2023[14] - Cash flow from operating activities for the first nine months of 2024 was CNY 30,123,285.58, slightly down from CNY 30,486,954.85 in the same period of 2023[22] - Cash inflow from investment activities in the first nine months of 2024 was CNY 501,561,954.91, significantly higher than CNY 277,523,786.03 in the previous year[22] - The net cash flow from financing activities for the first nine months of 2024 was -CNY 156,748,958.15, compared to -CNY 5,784,948.29 in the same period of 2023, indicating a substantial increase in cash outflow[22] Acquisitions and Impairments - The company completed the acquisition of a portion of Zhejiang Fuli Analytical Instrument Co., which contributed RMB 45.77 million to the consolidated revenue in Q3 2024[8] - The company recognized a goodwill impairment provision of RMB 23 million for the quarter, significantly impacting net profit[8] - The company recognized goodwill impairment of RMB 23.39 million for the acquisition of Saipu Instruments due to market adjustments in the biopharmaceutical and in vitro diagnostics sectors[13] Revenue and Costs - Total operating revenue for Q3 2024 reached ¥549,753,972.67, an increase of 22% compared to ¥451,155,239.81 in Q3 2023[18] - Total operating costs for Q3 2024 were ¥483,916,410.38, up from ¥422,357,702.51 in Q3 2023, reflecting a 14.6% increase[18] - Operating profit for Q3 2024 was ¥46,121,451.81, compared to ¥33,839,440.19 in Q3 2023, representing a growth of 36.1%[18] - Sales revenue from chromatography fillers and chromatography media decreased by 1.74% year-on-year to RMB 316 million, primarily due to increased economic uncertainty and tightened financing in the biopharmaceutical industry[13] Equity and Shareholder Information - The company's equity attributable to shareholders was ¥1,713,412,547.32 in Q3 2024, up from ¥1,703,527,946.74 in Q3 2023[16] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.1045, up from CNY 0.0966 in Q3 2023, reflecting an increase of approximately 9.9%[20]

独立财务顾问报告 2024 年 10 月 证券简称：纳微科技 证券代码：688690 上海荣正企业咨询服务（集团） 股份有限公司 关于 苏州纳微科技股份有限公司 2024 年限制性股票激励计划 预留授予相关事项 之 | 一、释义 | 3 | | --- | --- | | 二、声明 | 4 | | 三、基本假设 | 5 | | 四、独立财务顾问意见 | 6 | | 五、备查文件及咨询方式 | 11 | 一、释义 1. 上市公司、公司、纳微科技：指苏州纳微科技股份有限公司。 2. 股权激励计划、限制性股票激励计划、本激励计划：指《苏州纳微科技 股份有限公司 2024 年限制性股票激励计划（草案）》。 3. 限制性股票、第二类限制性股票：符合激励计划授予条件的激励对象在 满足相应的获益条件后分次获得并登记的公司 A 股普通股股票。 4. 股本总额：指公司股东大会审议通过本计划时公司已发行的股本总额。 5. 激励对象：按照本激励计划规定，获得限制性股票的公司（含全资、控 股子公司，下同）任职的董事、高级管理人员、核心技术人员及骨干员工。 6. 授予日：指公司向激励对象授予限制性股票的日期，授予日必须为交易 日。 7 ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-072 苏州纳微科技股份有限公司 关于调整2022年、2024年限制性股票激励计划 授予价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"纳微科技"或"公司"）于2024年 10月28日召开第三届董事会第三次会议，审议通过了《关于调整2022年、2024年 限制性股票激励计划授予价格的议案》，同意根据《苏州纳微科技股份有限公司 2022年限制性股票激励计划（草案）》及《苏州纳微科技股份有限公司2024年限 制性股票激励计划（草案）》的相关规定，对2022年及2024年限制性股票激励计 划授予价格（含预留部分）进行调整，2022年限制性股票激励计划的授予价格由 34.82616元/股调整为34.77616元/股，2024年限制性股票激励计划的授予价格由 18元/股调整为17.95元/股。现将相关调整内容公告如下： 一、 限制性股票激励计划已履行的相关审批程序 （一）2022 年限制性股票激励计划已履行的相关审批程序 ...

苏州纳微科技股份有限公司 限制性股票激励计划预留授予的分配情况： 2024 年限制性股票激励计划预留授予激励对象名单 2024 年 10 月 30 日 （预留授予日） | 姓名 | 国籍 | 职务 | 预留获授的 限制性股票 | 占授予限制 性股票总数 | 占授予时总股 本的比例 | | --- | --- | --- | --- | --- | --- | | | | | 数量 （万股） | 的比例 | | | 一、董事、高级管理人员、核心技术人员 | | | | | | | 林东强 | 中国 | 董事 | 4.60 | 0.70% | 0.01% | | 小计 | | | 4.60 | 0.70% | 0.01% | | 二、其他激励对象 | | | | | | | 骨干员工（68 人） | | | 105.40 | 15.97% | 0.26% | | 预留授予限制性股票合计（69 | | 人） | 110.00 | 16.67% | 0.27% | 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股 票均未超过公司总股本的 1%。公司全部有效期内的激励计划所涉及的标的股票总数累 ...